Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

BACKGROUND: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Valle, Juan W, Wasan, Harpreet, Lopes, Andre, Backen, Alison C, Palmer, Daniel H, Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D Alan, Corrie, Pippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J, Waters, Justin S, Steward, Will P, Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648082/
https://www.ncbi.nlm.nih.gov/pubmed/26179201
http://dx.doi.org/10.1016/S1470-2045(15)00139-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648082/
https://www.ncbi.nlm.nih.gov/pubmed/26179201
http://dx.doi.org/10.1016/S1470-2045(15)00139-4

Ejemplares similares